Save Product
Product Details
Synonyms
CD4, CD4mut, LEU3
Source
Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (CD4-HA225) is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Trp 390 (Accession # AAH25782). It is the Alexa Fluor™ 488 labeled form of Human CD4, His Tag (Cat. No. LE3-H5228).
Predicted N-terminus: Lys 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 41.5 kDa.
Conjugate
AF488
Excitation Wavelength: 488 nm
Emission Wavelength: 517 nm
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with AF488 using standard chemical labeling method. The residual AF488 is removed by molecular sieve treatment during purification process.
Protein Ratio
The AF488 to protein molar ratio is 2-4.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA225) at 1 μg/mL (100 μL/well) can bind Anti-CD4 Antibody (Ibalizumab-IgG4) with a linear range of 0.1-8 ng/mL (Routinely tested). Labeling with fluorescent dyes did not affect their activity.
Protocol
Bioactivity-Flow Cytometry
1e5 of Mouse Anti-CD4 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA225) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
Protocol
1e5 of Mouse Anti-CD4 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA225) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
T-cell surface antigen CD4
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
25 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
